Biogen Pharmachem Industries Share Price
0.27-0.01 (-3.57%)
-65.29% past 1 Year
Sun Techno Overseas Ltd is engaged in the business of trading in shares and securities small level of stock broking and consulting works. The company has also started trading operations
Corporate filings & documents
Announcements
PFA
4 weeks agoPFA
4 weeks agoPFA
4 weeks agoPFA
4 weeks agoPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Wednesday 5th August 2026. at the Registered Office of the Company and transacted the following major businesses:1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June 2026.The board meeting commented at 03:15 PM and concluded at 03:35 PMPlease take the above intimation in your records.Thanking You.
1 month agoPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Wednesday 5th August 2026. at the Registered Office of the Company and transacted the following major businesses:1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June 2026.The board meeting commented at 03:15 PM and concluded at 03:35 PMPlease take the above intimation in your records.Thanking You.
1 month agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th August 2026 inter alia to consider following businesses: -1 To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2026.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
1 month agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th August 2026 inter alia to consider following businesses: -1 To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2026.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
1 month agoPFA
1 month agoPFA
1 month agoPFA
2 months agoPFA
2 months agoPFA
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rama Shiva Lease Finance Pvt Ltd
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rama Shiva Lease Finance Pvt Ltd
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Parichay Infrastructure Ltd
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Parichay Infrastructure Ltd
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Interface Financial Services Ltd
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Interface Financial Services Ltd
3 months agoPFA
3 months agoPFA
3 months agoPFA
3 months agoPFA
3 months agoThis is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations 2015 has been approved by the Board of Directors of the Company and taken on record inter-alia the following items;1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March 2026.2.) Independent Auditors Report in pursuance with Regulation 33 of SEBI (LODR) Regulations 2015 for the F.Y. 31st March 2026.Further we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 for the financial year ended on March 31 2026 with Unmodified Opinion. The board meeting commenced at 04.00 PM and concluded at 04:30 PM.We request you to kindly take on record the same.Thanking You.
3 months agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Thursday 14th May 2026 inter alia to consider following businesses: -1.) Approve and take on record the Audited Standalone Financial Results of the Company for the quarter and year ended on 31st March 2026 along with the Reports of the Auditors thereon.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
4 months agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Thursday 14th May 2026 inter alia to consider following businesses: -1.) Approve and take on record the Audited Standalone Financial Results of the Company for the quarter and year ended on 31st March 2026 along with the Reports of the Auditors thereon.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
4 months agoPFA
4 months agoResults of Postal Ballot Notice Dated 23rd March 2026
4 months agoResults of Postal Ballot Notice Dated 23rd March 2026
4 months agoPFA
4 months agoPFA
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Biogen Pharmachem Industries Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L51100GJ1995PLC026702</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: KHUSHBOO KHANDELWAL <br/> Designation: COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: KELAH BUNKAR <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 22/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPursuant to Second proviso to Regulation 30(6) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Monday 23rd March 2026 at the Registered Office of the Company and transacted the major businesses which are attached in pdf.The board meeting commented at 07:00 PM and concluded at 07:30 PMPlease take the above intimation in your records.Thanking You.
5 months agoPursuant to Second proviso to Regulation 30(6) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Monday 23rd March 2026 at the Registered Office of the Company and transacted the major businesses which are attached in pdf.The board meeting commented at 07:00 PM and concluded at 07:30 PMPlease take the above intimation in your records.Thanking You.
5 months agoPFA
5 months agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/03/2026 inter alia to consider and approve issue of bonus shares in accordance with the applicable provisions and subject to approval of Shareholders of the Company.
6 months agoBiogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/03/2026 inter alia to consider and approve issue of bonus shares in accordance with the applicable provisions and subject to approval of Shareholders of the Company.
6 months agoPFA
6 months agoPFA
6 months agoPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Wednesday 11th February 2026 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and nine months ended as on 31st December 2025.The board meeting commenced at 03:30 PM and concluded at 04:00 PMPlease take the above intimation in your records.Thanking You.
6 months agoAPPOINTMENT OF STATUTORY AUDITOR TO FILL THE CASUAL VACNACY.
6 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2026-05-15
Bonus
1:6
Company details
Registered office
Shop No. 8, First Floor Makers - 1 Building Jawahar Road Rajkot Gujarat PIN: 360001 Tel No: NULL Fax No: NULL Email: [email protected] Internet: http:///www.biogenpharma.bar
Registrars
Office No A 106 & 107, Dattani Plaza, East West Compound, Andheri Kurla Road,Safedpul, Sakinaka, Mumbai-400072022-28520461/462 Office No A 106 & 107, Dattani Plaza East West Compound, Andheri Kurla Road Safedpul, Sakinaka PIN: Tel No: 022-28520461/462 Fax No: NULL Email: [email protected]
Management
Chandrakant Govindbhai Parmar, Non Executive Director
Kelash Bunkar, Whole Time Director & Chief Financial Officer
Chhaya Parmar, Non Executive Independent Director
Narendrakumar Vaniya, Non Executive Independent Director
Aman Patel, Non Executive Independent Director
Harshad Rathod, Non Executive Independent Director
Khushboo Khandelwal, Company Secretary & Compliance Officer
Details
BSE 531752
NSE NULL
ISIN INE703D01023